JP2021532094A5 - - Google Patents

Info

Publication number
JP2021532094A5
JP2021532094A5 JP2021502836A JP2021502836A JP2021532094A5 JP 2021532094 A5 JP2021532094 A5 JP 2021532094A5 JP 2021502836 A JP2021502836 A JP 2021502836A JP 2021502836 A JP2021502836 A JP 2021502836A JP 2021532094 A5 JP2021532094 A5 JP 2021532094A5
Authority
JP
Japan
Prior art keywords
stem cells
human
pharmaceutical composition
mitochondrial
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502836A
Other languages
English (en)
Japanese (ja)
Other versions
JP7458368B2 (ja
JP2021532094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2019/050826 external-priority patent/WO2020021539A1/en
Publication of JP2021532094A publication Critical patent/JP2021532094A/ja
Publication of JP2021532094A5 publication Critical patent/JP2021532094A5/ja
Application granted granted Critical
Publication of JP7458368B2 publication Critical patent/JP7458368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502836A 2018-07-22 2019-07-22 筋疾患のミトコンドリア増強療法 Active JP7458368B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862701783P 2018-07-22 2018-07-22
US62/701,783 2018-07-22
US201862753937P 2018-11-01 2018-11-01
US62/753,937 2018-11-01
PCT/IL2019/050826 WO2020021539A1 (en) 2018-07-22 2019-07-22 Mitochondrial augmentation therapy of muscle diseases

Publications (3)

Publication Number Publication Date
JP2021532094A JP2021532094A (ja) 2021-11-25
JP2021532094A5 true JP2021532094A5 (2) 2022-06-28
JP7458368B2 JP7458368B2 (ja) 2024-03-29

Family

ID=69181527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502836A Active JP7458368B2 (ja) 2018-07-22 2019-07-22 筋疾患のミトコンドリア増強療法

Country Status (4)

Country Link
US (1) US11951135B2 (2)
EP (1) EP3823640A4 (2)
JP (1) JP7458368B2 (2)
WO (1) WO2020021539A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
US11951135B2 (en) 2018-07-22 2024-04-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
AU2019311859B2 (en) 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7586811B2 (ja) * 2018-07-22 2024-11-19 ミノヴィア セラピューティクス リミテッド 腎臓疾患のミトコンドリア増強療法
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
AU2021248780A1 (en) * 2020-03-31 2022-11-10 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
CA3239683A1 (en) * 2021-12-13 2023-06-22 Natalie YIVGI-OHANA Mitochondrial augmentation therapy for myelodysplastic syndrome
CN117883479A (zh) * 2023-11-02 2024-04-16 上海市第六人民医院 人源线粒体在制备治疗跟腱损伤的药物中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2186636A1 (en) 1994-03-30 1995-10-12 Corinna Herrnstadt Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
EP1119368A2 (en) 1999-03-03 2001-08-01 Biogen, Inc. Methods of modulating lipid metabolism and storage
GB2350565A (en) 1999-05-28 2000-12-06 Johnson & Johnson Medical Ltd Biological wound dressings comprising mitochondria
DE19937348A1 (de) 1999-08-11 2001-02-22 Aventis Cropscience Gmbh Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind
WO2002030418A1 (fr) 2000-10-13 2002-04-18 Chugai Seiyaku Kabushiki Kaisha Compositions servant a ameliorer le metabolisme lipidique
US20030040475A1 (en) 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
US7339090B2 (en) 2001-02-13 2008-03-04 Avigenics, Inc. Microinjection devices and methods of use
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
AU2002330938A1 (en) 2001-07-31 2003-02-17 Northeastern University Mitochondrial genome replenishment
US20050153381A1 (en) 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
CA2525560A1 (en) 2003-05-13 2004-11-25 The Regents Of The University Of Colorado Diagnostic and therapeutic treatments related to mitochondrial disorders
EP1626732B1 (en) 2003-05-22 2013-04-03 CHIESI FARMACEUTICI S.p.A. Means for preventing and treating cellular death and their biological applications
US7407800B1 (en) 2003-09-19 2008-08-05 Pierce Biotechnology, Inc. Method for the isolation of intact mitochondria from cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
US20060024277A1 (en) 2004-07-27 2006-02-02 Sivak Hannah N Method of skin care and/or treatment using extracts enriched in mitochondria
CA2609208C (en) 2005-06-10 2016-10-18 Per-Ake Albertsson Use of plant cell membrane for the treatment of obesity
AU2012201710B2 (en) 2006-05-11 2014-01-16 Regenics As Administration of cells and cellular extracts for rejuvenation
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
US9603872B2 (en) 2007-05-02 2017-03-28 The McLeon Hospital Corporation Methods and compositions for mitochondrial replacement therapy
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
JP5866601B2 (ja) 2008-06-18 2016-02-17 ザ テキサス エーアンドエム ユニバーシティ システムThe Texas A&M University System 医薬組成物の製造方法
WO2011059547A2 (en) 2009-10-30 2011-05-19 Xenotech, Llc Cryopreservation of cells and subcellular fractions
US8846028B2 (en) 2010-10-28 2014-09-30 The Invention Science Fund I, Llc Mitochondrial enhancement of cells
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
PH12022550598A1 (en) 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
EA201490050A1 (ru) 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
US20130022666A1 (en) 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
US8648034B2 (en) 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
WO2013149064A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
WO2013171752A1 (en) 2012-05-16 2013-11-21 Minovia Therapeutics Ltd. Compositions and methods for inducing angiogenesis
EP3459522B1 (en) 2012-12-10 2021-02-17 Regenics AS Use of egg cellular extracts for wound treatment
DE102013225588A1 (de) 2013-12-11 2014-04-17 Henkel Ag & Co. Kgaa Verwendung und Mittel zur Verbesserung der Haarstruktur
AU2015214145A1 (en) 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
EP2918458B1 (en) 2014-03-11 2016-12-07 Autoliv Development AB A vehicle braking arrangement
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
WO2016008937A1 (en) 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
JP6441472B2 (ja) 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Taiwan Mitochondrion Applied Technology Co.,Ltd. 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
JP6644702B2 (ja) * 2014-11-14 2020-02-12 Jcrファーマ株式会社 歯髄由来多能性幹細胞を含有する筋ジストロフィー治療剤
GB201500427D0 (en) 2015-01-12 2015-02-25 Isis Innovation Method
US20180007913A1 (en) 2015-01-14 2018-01-11 Calix Ltd Improved pathogen inhibitor
IL299482B2 (en) 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
MA41757A (fr) 2015-02-27 2018-01-03 Univ Connecticut Transplantation ciblée de mitochondries dans des hépatocytes
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
KR20190109389A (ko) 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
JP7187036B2 (ja) 2016-11-14 2022-12-12 パイアン バイオテクノロジ- インコーポレイテッド 外因性ミトコンドリアを細胞内に送達する方法
JP2020502078A (ja) 2016-11-30 2020-01-23 パイアン・バイオテクノロジー・インコーポレイテッドPaean Biotechnology Inc. ミトコンドリアを含む医薬組成物
WO2018178970A1 (en) 2017-03-26 2018-10-04 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
AU2019311859B2 (en) 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
EP3823643A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF LIVER DISEASES
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
US20210322485A1 (en) 2018-07-22 2021-10-21 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
US11951135B2 (en) 2018-07-22 2024-04-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
US20200054682A1 (en) 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
CN121610569A (zh) 2019-04-30 2026-03-06 拉利玛生物医药公司 用于测定共济蛋白替代疗法的疗效的共济蛋白敏感性标志物
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas

Similar Documents

Publication Publication Date Title
JP2021532094A5 (2)
JP2021532091A5 (2)
Zhidu et al. Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities
Kumar et al. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine
Galderisi et al. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years?
JP2021532095A5 (2)
Dabrowska et al. Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: therapeutic outlook for inflammatory and degenerative diseases
JP2021532093A5 (2)
Shabbir et al. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen
JP2021531288A5 (2)
US5130141A (en) Compositions for and methods of treating muscle degeneration and weakness
Nair et al. Stem cell therapy in heart failure: Where do we stand today?
Lee et al. Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease
US8354370B2 (en) Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders
JP2022519409A5 (2)
Smolinska et al. Current status of the applications of conditioned media derived from mesenchymal stem cells for regenerative medicine
JP2021531284A5 (2)
RU2014108878A (ru) Лечение заболевания периферических сосудов при помощи клеток, полученных из ткани пуповины
CN104955470B (zh) 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
Zhou et al. Therapeutic effects of adipose-derived stem cells-based microtissues on erectile dysfunction in streptozotocin-induced diabetic rats
Rosca et al. Emerging role of stem cells-derived exosomes as valuable tools for cardiovascular therapy
JP2019513010A (ja) プロスタグランジンe2を用いる、筋再生のための組成物および方法
JP2021531281A5 (2)
Wang et al. Role of mesenchymal stem cells in sepsis and their therapeutic potential in sepsis-associated myopathy
Lian et al. In vivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin I synthase gene improves cardiac performance in mice